| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation (NCT04781855) | M.D. Anderson Cancer Center | 2022-07-14 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (NCT05246345) | University Hospital, Clermont-Ferrand | 2022-03-07 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome (NCT04978779) | Vincerx Pharma, Inc. | 2021-12-16 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study (NCT04230304) | Mayo Clinic | 2020-11-11 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737) | M.D. Anderson Cancer Center | 2020-07-29 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03961672) | City of Hope Medical Center | 2020-05-13 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas (NCT04305444) | Zhejiang DTRM Biopharma | 2020-04-24 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor (NCT03884972) | M.D. Anderson Cancer Center | 2019-06-18 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038) | M.D. Anderson Cancer Center | 2019-05-15 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
| Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL (NCT03045328) | Steven E. Coutre | 2017-09-26 |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia (NCT02948283) | City of Hope Medical Center | 2017-09-05 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 (NCT03185494) | Chinese PLA General Hospital | 2017-08-01 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770) | Chinese PLA General Hospital | 2017-04-01 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant (NCT02869633) | Vanderbilt-Ingram Cancer Center | 2016-11-01 |
| Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma (NCT03110640) | First Affiliated Hospital of Wenzhou Medical University | 2016-10-01 |
| Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCT02756897) | M.D. Anderson Cancer Center | 2016-07-07 |
| Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02225275) | M.D. Anderson Cancer Center | 2016-03-31 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (NCT02685670) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2016-02-01 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02614508) | Emory University | 2016-01-01 |
| Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia (NCT02427451) | Kerry Rogers | 2015-08-03 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation (NCT02420912) | M.D. Anderson Cancer Center | 2015-06-19 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma (NCT02303392) | Jennifer Woyach | 2015-06-09 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980) | Mayo Clinic | 2015-02-19 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT02168907) | Wake Forest University Health Sciences | 2014-12-01 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT02240719) | University of California, Davis | 2014-10-01 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (NCT02109224) | National Cancer Institute (NCI) | 2014-09-01 |
| Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02160015) | National Cancer Institute (NCI) | 2014-05-20 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (NCT02005289) | Ohio State University Comprehensive Cancer Center | 2014-01-17 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01886859) | National Cancer Institute (NCI) | 2013-04-26 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy (NCT01735604) | Chinese PLA General Hospital | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (NCT01567709) | National Cancer Institute (NCI) | 2012-04-16 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (NCT01475058) | Fred Hutchinson Cancer Center | 2012-04-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01515176) | National Cancer Institute (NCI) | 2012-01-01 |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia (NCT01441882) | OHSU Knight Cancer Institute | 2011-10-01 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01369849) | National Cancer Institute (NCI) | 2011-09-01 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (NCT01658319) | Case Comprehensive Cancer Center | 2011-05-01 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (NCT01231919) | National Cancer Institute (NCI) | 2011-01-01 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia (NCT01269385) | Mayo Clinic | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01251575) | Fred Hutchinson Cancer Center | 2010-12-01 |
| Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia (NCT01251250) | Roswell Park Cancer Institute | 2010-12-01 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) (NCT01212380) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01126502) | National Cancer Institute (NCI) | 2010-05-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01076556) | National Cancer Institute (NCI) | 2010-04-01 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (NCT01008462) | Fred Hutchinson Cancer Center | 2010-03-18 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy (NCT01029366) | University of Pennsylvania | 2010-03-17 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (NCT01044745) | University of Nebraska | 2009-12-10 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (NCT00918333) | Mayo Clinic | 2009-06-01 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (NCT00933985) | National Cancer Institute (NCI) | 2009-06-01 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (NCT00867529) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment (NCT00845104) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2009-01-01 |
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) (NCT00947388) | Case Comprehensive Cancer Center | 2008-11-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (NCT00711828) | Mayo Clinic | 2008-08-01 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00735930) | National Cancer Institute (NCI) | 2008-08-01 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia (NCT00612612) | National Cancer Institute (NCI) | 2008-01-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00398112) | National Cancer Institute (NCI) | 2007-08-01 |
| Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma (NCT00621452) | Fred Hutchinson Cancer Center | 2007-08-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia (NCT00366418) | National Heart, Lung, and Blood Institute (NHLBI) | 2006-08-10 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (NCT00321724) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia (NCT00301769) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib and Bortezomib in Treating Patients With Advanced Cancer (NCT00303797) | National Cancer Institute (NCI) | 2005-12-01 |
| Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00290810) | National Cancer Institute (NCI) | 2005-12-01 |